Clinical Trials on Nonsmall Cell Lung Cancer, Stage IV in Hong Kong

Total 283 results

Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Australia, Belgium, France, Italy, Hong Kong, Canada, Denmark, Taiwan, Russian Federation, United Kingdom, Spain, Hungary, Czech Republic, Poland, Germany, Netherlands
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Canada, Ireland, Peru, South Africa
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma

United States
Xcovery Holdings, Inc.

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Hong Kong, United Kingdom, Poland, Israel, Germany, France, Argentina, Australia, Brazil, Canada, Czechia, Italy, Netherlands, Russian Federation, Turkey, Belgium
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

ALK-positive Non-small Cell Lung Cancer

United States, France, Italy, United Kingdom, Taiwan, Turkey, Belgium, Germany, Canada, Singapore, Spain, Korea, Republic of, Netherlands, Russian Federation, Brazil, Hong Kong, Australia
Amgen

Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

United States, Spain, Austria, Switzerland, United Kingdom, France, Australia, Germany, Japan, Taiwan, Poland, Hong Kong, Netherlands
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer (ALPINE)

Stage IV Pancreatic Cancer

United States
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)

Carcinoma | Non Small Cell Lung

United States, France, Canada, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Bulgaria, Estonia, India, Malaysia, Singapore, Taiwan, Czech Republic, Argentina, Finland, Hungary, Korea... and more
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Lung Cancer

United States
Gilead Sciences
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

Non-small Cell Lung Cancer

United States, Spain, Italy, France, Australia, Hong Kong, Korea, Republic of, Malaysia, Taiwan, Germany, United Kingdom, Canada
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Proacta, Incorporated

Terminated

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Lung Cancer

United States
Novartis Pharmaceuticals

Completed

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United Kingdom, Taiwan, Belgium, Spain, Canada, Italy, Singapore, Japan, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Norway, Australia, France, Sweden, United States, New Zealand
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Breast Cancer | Stage IV Breast Cancer

United States, Canada, Israel, Saudi Arabia, South Africa
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (BASALT-1)

Non-small Cell Lung Cancer

France, Italy, United Kingdom, Hungary, Belgium, Canada, Spain, Germany, Singapore, Netherlands, Thailand, United States, Turkey, Argentina, Brazil, Hong Kong, Japan, Taiwan
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Advanced Non-Small Cell Lung Cancer

Poland, Russian Federation, United States, Australia, Canada, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Eli Lilly and Company

Completed

Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

China
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine... and other conditions

United States, Korea, Republic of, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Terminated

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Lung Cancer | Pulmonary Complications | Radiation Fibrosis

United States
Tasly Pharmaceuticals, Inc.

Unknown

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

United States
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Metastatic Non-Small Cell Lung Cancer

France, Spain, United States, Italy, Canada, Taiwan, Hong Kong, Japan, Turkey, Korea, Republic of, United Kingdom, Germany, Romania, Greece
HUYABIO International, LLC.

Recruiting

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Cancer | Colorectal Cancer | Lung Cancer | Solid Tumor | Non Small Cell Lung Cancer | Colon Cancer | Cancer of Pancreas

United States, Puerto Rico
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Non-small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, China, Hong Kong, France, Russian Federation, Netherlands, Japan, Spain, Italy, Belgium, Vietnam, Malaysia, Thailand, Germany, Singapore
Genzyme, a Sanofi Company

Completed

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients (ZEAL)

Lung Cancer | Non Small Cell Lung Cancer

United States, Australia, France, Italy, South Africa, Spain, United Kingdom, Sweden, Philippines, Germany, Hong Kong, Argentina, Israel, Portugal, Greece, Taiwan, Mexico, Belgium, Venezuela, Colombia, India
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Spain, Hong Kong, Argentina, China, Netherlands, France, Brazil, Belgium, Canada, Germany, Greece, Italy, Japan, Turkey, Ukraine
Pfizer

No longer available

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer

Belgium, Israel, Italy, Spain, Hong Kong, Taiwan, Canada, France, Greece, Russian Federation, Czech Republic, Australia, Bulgaria, Germany, Thailand, Hungary, United Kingdom, Argentina, Brazil, Poland
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Eisai Inc.

Completed

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Taiwan, Hong Kong, Spain, Poland, Singapore, Russian Federation, Italy, Australia, France, Germany, Japan, United Kingdom, Korea, Republic of

Clinical Trials on Nonsmall Cell Lung Cancer, Stage IV in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations